Autism Clinical Trial: Now Enrolling

IRIS

Does autism affect your life or the life of someone you love?

gradient-divider

MapLight Therapeutics is recruiting patients for IRIS, a Phase 2 clinical trial evaluating ML-004, the company’s clinical compound for patients with Autism Spectrum Disorder. The study will assess whether there is an impact of ML-004 treatment on the core social communication deficits and on the associated features of irritability in ASD. 

The randomized, double blind, placebo-controlled study will evaluate the efficacy and safety profile of ML-004 in up to 150 adults and adolescents with ASD. The study will be conducted in the United States, Australia, and Canada, and is fully funded by MapLight.

For more details on the study, and to contact participating sites near you, visit the study page at ClinicalTrials.gov.

About the clinical trial​

gradient-divider

The IRIS clinical trial is evaluating an oral investigational medication, ML-004, to see if it may help alleviate some of the symptoms that interfere with communication in those with autism spectrum disorder (ASD).

Participants may be able to take part in the clinical trial if they:

  • Are between the ages of 12 and 45 years old
  • Have a diagnosis of autism spectrum disorder (ASD)
  • Have a clinical trial/care partner* willing to assist during the trial

*The clinical trial/care partner is someone who lives with or has frequent contact with the clinical trial participant (parent, spouse, friend, etc.) and is willing and able to provide information about the participant and attend some trial visits. 

The clinical trial team will discuss additional eligibility criteria with you.

Study Sites Currently Screening and Enrolling Patients

Please provide a valid CSV file.